High-dose Vitamin C Blocks HOCl Production by Myeloperoxidase: A Potential Therapeutic Strategy
Alexander V. PeskiniD, Nicholas J. MagoniD, Stephanie M. BozonetiD
Abstract
High-dose vitamin C therapy for cancer, originally advocated by Linus Pauling (Proc Natl Acad Sci, 1976, 73, 3685-3689), remains a subject of ongoing debate. In this study, we investigate why only pharmacological doses are effective and explore the reasons behind inconsistent therapeutic outcomes. Our data suggest that the bona fide cause of toxicity was oxidized vitamin C rather than hydrogen peroxide. We found that vitamin C at millimolar concentrations, directly inhibits hypochlorous acid generation by myeloperoxidase, through competition with chloride rather than by scavenging the hypochlorous acid that is formed. Products of vitamin C oxidation reacted with the thiols of peroxiredoxin 2 and GAPDH, but failed to react with the cysteine of p16INK4a. The growth and viability of Jurkat cells were affected by oxidized vitamin C. These experiments were conducted in the presence of catalase, demonstrating that the biological effects were due to the products of vitamin C oxidation and not hydrogen peroxide. These findings may have practical implications for the treatment of cancer and diseases in which the deleterious effects of neutrophil activation are observed. For intravenous administration of pharmacological vitamin C to have a beneficial effect, its concentration in the blood must be maintained at millimolar levels and this can only be achieved via maintenance infusion. As a proof-of-concept, our data suggest that to enhance anticancer therapy interventions, it is crucial to implement treatments that facilitate the oxidation of vitamin C in the bloodstream.O_QDProgress in the art of healing has always been induced by progress in basic knowledge. C_QD O_QDAlbert Szent-Gyorgyi (Woods Hole, Mass., USA, 1973) C_QD Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=63 SRC="FIGDIR/small/627077v4_ufig1.gif" ALT="Figure 1"> View larger version (18K): org.highwire.dtl.DTLVardef@1fef8c6org.highwire.dtl.DTLVardef@7ebe59org.highwire.dtl.DTLVardef@102e623org.highwire.dtl.DTLVardef@153252d_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 1.11
- Field percentile
- top 26%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Large pan-cancer cell screen coupled to (phospho-) proteomics underscores high-dose vitamin C as a potent anti-cancer agent
A. Valles Marti, F. Böttger, … C. R. Jimenez·bioRxiv·Dec 19, 2023
- Short-term oxaliplatin exposure according to established hyperthermic intraperitoneal chemotherapy (HIPEC) protocols lacks effectiveness in vitro and ex vivo
M. W. Löffler, N. Seyfried, … S. Beckert·bioRxiv·Jul 31, 2019
- Vitamin C functions as double-edge sword on cancer progression depending on ERK activation or inhibition mediated by its receptor SVCT2
Yian Guan, Bingxue Chen, … Zekun Guo·bioRxiv·Jan 11, 2022
- Iron-catalyzed antagonism between NO and H2O2 / HOCl causes mutual exclusivity of HOCl- and NO/peroxynitrite-mediated apoptosis-inducing signaling
G. Bauer·bioRxiv·Jul 3, 2022
- Lysine vitcylation is a novel vitamin C-derived protein modification that enhances STAT1-mediated immune response
X. He, Y. Wei, … J. J. Zhao·bioRxiv·Jun 27, 2023
- Targeting C5aR1 Increases the Therapeutic Window of Radiotherapy
M. M. Olcina, S. Melemenidis, … A. J. Giaccia·bioRxiv·Oct 27, 2020